United Kingdom
Sarah Cannon Research Institute
Non-small cell lung cancer, NSCLC, immune checkpoint inhibitors, anti-TIGIT monoclonal antibody, PD-L1 inhibitor, atezolizumab, tiragolumab, cancer immunotherapy
Nivolumab, atigotatug, extensive-stage small cell lung cancer, innate immune inducer, Fuc-GM1